CORONA Remedies snaps up Wokadine to boost antiseptic play 

Key Highlights: 

• CORONA Remedies has acquired the Wokadine brand from Dr. Reddy’s Laboratories, effective March 30, 2026, strengthening its presence in the povidone-iodine segment in India 

• Wokadine, ranked #2 in the povidone-iodine market, adds a well-established antiseptic brand to CORONA’s portfolio, enabling deeper penetration into targeted specialties and expanding access across its pan-India distribution network 

• The acquisition aligns with CORONA’s inorganic growth strategy, leveraging its strong physician relationships and commercial infrastructure to accelerate Wokadine’s growth and reinforce its broader healthcare portfolio expansion  

Implications: 

CORONA Remedies is using the Wokadine acquisition to buy its way into India’s ₹648 crore povidone-iodine market with a #2-ranked, 46‑year-old antiseptic brand that already has strong equity among surgeons, ENTs, GPs, and gynaecologists. 

By plugging Wokadine’s 14 SKUs into its pan‑India field force and specialty‑focused portfolio, CORONA can deepen engagement in hospital and clinic segments while executing its inorganic growth playbook of scaling established brands rather than building from scratch. 

Source: Expresspharma  |  Image: CORONA Remedies